Cassava Announces Closure of U.S. Department of Justice Investigation
AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the U.S. Department of Justice Fraud Section (DOJ) has closed its inquiry into the Company regarding allegations of research misconduct as described in the indictment in United States v. Wang, 8:24-cr-000211-TDC (D. Md.). That indictment was dismissed with prejudice by DOJ on October 23, 2025.
As previously disclosed, the Company reached a settlement with the U.S. Securities and Exchange Commission (SEC) of negligence-based disclosure charges in September 2024 and paid a monetary penalty without admitting or denying the SEC’s allegations.
The Company cooperated fully with both the DOJ and SEC investigations. These outcomes end the investigations of the Company by the DOJ and SEC.
“We welcome the resolution of these investigations and remain dedicated to maintaining the trust of all our stakeholders. As we move forward, we will continue to focus our efforts on developing a novel treatment for TSC-related epilepsy,” said Richard J. Barry, President and Chief Executive Officer of Cassava.
About Cassava Sciences, Inc.
Cassava Sciences, Inc. (NASDAQ: SAVA), is a biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and potentially other indications.
For more information, please visit: https://www.CassavaSciences.com
Company
Eric Schoen, Chief Financial Officer
(512) 501-2450
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
XRP Beats Bitcoin in August With a 30% Monthly Gain

Fitness+ business streamlining, $1999 foldable screen and AI strategy take the lead! Apple (AAPL.US) is brewing a new round of strong growth
A more significant catalyst for future performance is the premium product structure upgrade driven by foldable screens, as well as a new wave of iPhone replacement demand prompted by Apple's exclusive AI experience that has been in the works for years.
Qualcomm (QCOM.US) Snapdragon Summit Preview: 2nm Dual-Chip Debuts, AI Diversification Narrative Faces Key Verification
Qualcomm is scheduled to hold its annual Snapdragon Summit in Maui, Hawaii, from September 22 to 24 local time.
SUI SuperTrend Flips to Buy — Macro Shift From Bearish to Bullish Begins

